The High That Was Already in the Cupboard

Here is a thing that is true about inhalant use disorder that is not true about any other form of substance use disorder: the substance is already in the house. It was there before the person using it was born. It was under the sink, on the garage shelf, in the supply closet at school — aerosol cleaning products, spray paint, glue, correction fluid, butane, nitrous oxide cartridges, markers with solvent-based ink. There is no dealer. There is no prescription. There is no transaction that marks the beginning of the use and could theoretically be interrupted. The substance is simply available, all the time, to anyone.

That fact shapes everything about this particular form of addiction: who develops it, when they develop it, how it goes unrecognized, why it is so poorly served by treatment systems designed around a different model of drug access, and why the people who have gone through it describe a particular species of shame that most recovery communities are not equipped to hold.

About 1 million Americans aged 12 and older use inhalants in a given year, according to SAMHSA survey data. Eighth graders are five times more likely to use inhalants than adults. The rates invert as people age — 4.8 percent of eighth graders report past-year use, 2 percent of tenth graders, 1.8 percent of twelfth graders — which is the opposite of the pattern for alcohol, cannabis, and most other substances. The earlier the use begins, the worse the clinical picture. And the people who develop inhalant use disorder — as distinct from adolescent experimentation — tend to be drawn from the most marginalized communities: school dropouts, homeless youth, Indigenous youth, young people in the child welfare system, adolescents with histories of physical or sexual abuse. The drug is free. That’s the whole point.

What the high is, and why it keeps happening

Inhalants produce their effect through CNS depression: the solvents and gases — toluene in spray paint, difluoroethane in air dusters, nitrous oxide in whippets — act on the central nervous system in a way that resembles alcohol and general anesthesia at low doses. The onset is almost immediate (seconds) and the euphoria is intense. The duration is very short: fifteen to forty-five seconds for a single inhalation. This brief window is not a safety feature. It is the mechanism that drives compulsive re-use within a single session.

Someone who is huffing does not typically huff once. They huff continuously, in rapid repeated cycles, chasing a high that lasts less than a minute each time. A single session can involve dozens of inhalations over a period of hours. This pattern distinguishes inhalant use from nearly every other form of drug use and creates a distinctive clinical picture: heavy exposure to toxic solvents across a compressed window, repeated multiple times per week or daily. The neurological damage that accumulates is not a function of a single dramatic event — it is the slow ruin of repeated small insults to a developing brain.

A peer-reviewed case report published in Interventional Cardiology documented a case of air duster inhalant abuse causing a non-ST elevation myocardial infarction in an adolescent — a heart attack, triggered by cardiac arrhythmia, in a person with no underlying cardiac disease. This is the mechanism of sudden sniffing death syndrome: the solvent sensitizes the heart muscle to adrenaline, and any sympathetic stimulus — running, a sudden fright, the startle of someone discovering the use — can trigger a fatal arrhythmia. Sudden sniffing death can occur on the very first use, with no warning and no prior tolerance. It is the reason that inhalant use carries a mortality risk profile that is distinct from most other substances: rather than accumulating risk over years of chronic use, it presents immediate cardiac danger from the first session.

Sudden sniffing death can occur on the very first use, with no warning and no prior tolerance.

Chronic users who survive the cardiac risk face a different and slower-moving form of harm. Toluene, the solvent in many spray paints and glues, is directly neurotoxic. Long-term toluene exposure produces white matter degeneration in the brain — the myelin sheaths that form the communication infrastructure of the nervous system are damaged and, in severe cases, destroyed. The clinical presentation of heavy chronic inhalant use — cognitive slowing, memory impairment, coordination problems, mood dysregulation — overlaps substantially with the presentation of traumatic brain injury. Some of the damage is reversible with prolonged abstinence; some is permanent. Clinicians working with people who have significant inhalant use histories often describe the rehabilitation process as more similar to working with brain injury than to working with opioid or alcohol recovery.

The silence in the rooms

People in recovery from opioids talk about opioids. People in recovery from alcohol talk about alcohol. The 12-step fellowships, the SMART Recovery groups, the peer support infrastructure that has developed over decades — it was built around the substances that were common enough and visible enough to generate a critical mass of shared experience.

Inhalant use disorder does not have that infrastructure. The people who have lived through it are often younger, often more socioeconomically marginalized, often starting from a place where the recovery community itself was not a space they could access. The shame is particular: explaining inhalant use disorder to someone who has never encountered it frequently involves explaining what it is, and how it works, and why a person would do it — a layer of disclosure that isn’t required when someone in a recovery room says “I’m an alcoholic.” Opioid use disorder has powerful, public advocates now. Inhalant use disorder does not.

Jermaine J. Williams, a peer recovery specialist in Illinois who received the Peer Specialist of the Year Award from NAADAC in 2026, described the experience of working with young clients whose SUD histories included inhalants as requiring a specific kind of de-stigmatization work. “People reached out to tell me that my honesty gave them courage,” he said, speaking about his own recovery story. “Seeing someone they respected speak openly made them feel less ashamed.” The courage gap is real — and for inhalant use disorder, in particular, the silence compounds the stigma.

Treatment for inhalant use disorder is behavioral. There are no FDA-approved medications for it, no pharmacological equivalent of buprenorphine or naltrexone that interrupts the mechanism of compulsive use. Cognitive behavioral therapy, contingency management, motivational interviewing, and family-systems approaches are the evidence-based options. Programs specifically designed for inhalant use disorder are rare; most treatment facilities address it within the broader framework of adolescent SUD treatment. This is not inherently wrong — the underlying behavioral mechanisms share enough with other substance use disorders that the tools transfer — but the neurological complexity of long-term inhalant use disorder, and the rehabilitation timeline that permanent white matter damage may require, are not always accounted for in standard 30-day residential models.

The population most at risk is the one least served

The demographics of inhalant use disorder track closely with the demographics of every other gap in the behavioral health system: Indigenous youth, homeless youth, children in the foster care system, young people in rural and low-income communities with limited access to mental health services. The substance is free. The programs to address the disorder are not.

SAMHSA’s National Survey on Drug Use and Health data consistently shows that inhalant use is concentrated in the youngest adolescent population and in communities where other risk factors — poverty, housing instability, adverse childhood experiences — compound the vulnerability. The 8th-grade peak-use statistic is not a trivia item; it reflects the fact that the typical inhalant user is twelve or thirteen years old, is using a substance that is cheaper than alcohol and easier to obtain, and is not yet in contact with a treatment system that would recognize the use as a clinical problem rather than a behavioral one.

Prevention programs for inhalant use should be reaching elementary school students. Treatment programs for inhalant use disorder should be staffed by people who understand the neurological complexity. Peer support infrastructure for people in recovery from inhalant use should exist at the scale that it exists for opioid use disorder. None of these things are true yet.

Peer support infrastructure for people in recovery from inhalant use should exist at the scale that it exists for opioid use disorder.

The substance was already in the house. The systems that might have interrupted the disorder — prevention, early identification, accessible treatment, peer community — weren’t.

Rize Recovery connects people in Arizona with substance-specific treatment resources, including programs with experience in adolescent SUD. Start at rizerecovery.com/find-help. For the inhalants section of our substance library, see /newsroom/substances/inhalants.